Medical Oncology

Nuclear Medicine

Questions discussed in this category

For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?

FDG PET, Axumin PET, Bone scan? Or just proceed with salvage ADT/RT?

4 Answers available

What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?

1 Answer available

How do you manage dry eye related to Pluvicto Lu-177?

2 Answers available

Would you consider 177Lu-Dotatate (Lutathera) in patients with midgut neuroendocrine carcinoma after treatment with a somatostatin analog but with Ki67 >20%?

This patient had a Ki67 of 27%. However, the inclusion criteria for the NETTER-1 Trial was Ki67<20%. Would Lutathera be an option if labs are withi...

2 Answers available

For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

2 Answers available

Can PRRT be used in a patient with a GI neuroendocrine tumor and estimated GFR of less than 30?

1 Answer available

Papers discussed in this category

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005-01

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

J. Nucl. Med.,

NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-DOTATATE Peptide Receptor Radionuclide Therapy.

Neuroendocrinology, 2017 Apr 13

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.

The New England journal of medicine, 2017-07-27

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014-12-10

Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer.

JAMA Oncol, 2021 Feb 18

Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.

Endocr Relat Cancer,

Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.

J Nucl Med, 2018 Aug 16

Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.

Eur J Nucl Med Mol Imaging, 2017 Sep 12

Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.

N Engl J Med, 2021 Jun 23

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

Clin Cancer Res, 2021 Feb 23

Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.

European urology, 2023 Jul 05

Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).

The Journal of urology, 2023 Apr 26

Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).

Related Topics in Medical Oncology